Abstract:Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies that evaluated the clinical efficacy and safety of various agents used in ATTR-CM, with a goal of identifying the contemporary gaps in literature and to reveal future research opportunities. Methods and results: The search was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search using several databases for observational and clinical trials investigating the treatment modalities for ATTR-CM was undertaken. We extracted data including study characteristics, primary endpoints, and adverse events from each study. A total of 19 studies were included in our scoping review. Out of which, 8 were clinical trials and 11 were observational analyses. The drugs evaluated included tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid and doxycycline, diflusinil, inotersan, eplontersen, and patisiran. Tafamidis has shown to be efficacious in the management of ATTR-CM, particularly when initiated at earlier stages. RNA interference and antisense oligonucleotide drugs have shown promising impacts on quality of life. Additionally, this review identified gaps in the literature, particularly among long-term outcomes, comparative effectiveness, and the translation of research into economic contexts. Conclusion: Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM. However, many gaps exist in the understanding of these various drug therapies, warranting further research. The future directions for management of ATTR-CM are promising in regard to improving prognostic implications.

The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis

Tubulin Post-translational Modifications: Potential Therapeutic Approaches to Heart Failure

Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

Heart failure: advanced development in genetics and epigenetics.

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors

Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy

Treatment of cardiac transthyretin amyloidosis: an update

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges

The conformational landscape of human transthyretin revealed by cryo-EM

The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?

Cell Therapy and 3D Regenerative Tissue to Remodel Heart Failure

Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy

Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

Human in vitro disease modeling of ATTR cardiac amyloidosis

Treatment of transthyretin cardiac amyloidosis

Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.